Philogen CEO Duccio Neri said: "We are excited to expand our collaboration with AbbVie, a leader in the field of antibody therapeutics.
"The first agreement between the companies focused on osteoarthritis, and we are continuing to explore the shared scientific strengths of both companies.”
No financial details of the agreement were released.